Skip to main content

Table 2 Clinical outcomes for RPL patients pursuing expectant management stratified by AMH level

From: Antimullerian hormone is a predictor of live birth in patients with recurrent pregnancy loss

Outcomes by AMH level: (n = 155 patients)

Age (Mean ± SD)

Pregnancies per patient, N (%)

LBR per pregnancy, N (%)

CMR per pregnancy, N (%)

Time to Pregnancy, months (Mean ± SD)

AMH < 0.5 (n = 28)

37.9 ± 4.0

14 (50%)

5 (36%)

9 (64%)

4.8 ± 3.7

AMH 0.5–0.99 (n = 19)

36.4 ± 3.1

14 (74%)

6 (43%)

8 (57%)

4.8 ± 2.7

AMH 1–1.99 (n = 41)*

35.3 ± 6.2

30 (73%)

17 (57%)

12 (40%)

3.9 ± 2.2

AMH 2–2.99 (n = 24)

35.0 ± 3.9

16 (67%)

12 (75%)

4 (25%)

4.6 ± 2.3

AMH ≥ 3 (n = 43)

33.7 ± 3.4

29 (67%)

21 (72%)

8 (28%)

4.6 ± 3.3

  1. *1 pregnancy was terminated for XYY karyotype on amniocentesis